Comparing How Long Blood-Thinning Drugs Are Taken After Heart Stenting in Kidney Disease
Compares two durations of dual blood-thinning drugs after heart stenting in advanced kidney disease.
Plain-language title generated from the registry record
Registry title: Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)
Key facts
- Where
- Seoul, South KoreaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 84 years old?
Source: NCT04708587, who can take part
Where in South Korea
- Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of MedicineSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Yonsei University
- Trial code
- NCT04708587
- Record updated
- 21 January 2026
- Original description
The purpose of this prospective randomized clinical trial is to compare the clinical outcomes according to the duration of aspirin and clopidogrel or prasugrel with dual anti-platelet therapy after percutaneous coronary intervention in patients with advanced chronic kidney disease using a new generation drug eluting stents.Read full original descriptionShow less
Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)
The purpose of this prospective randomized clinical trial is to compare the clinical outcomes according to the duration of aspirin and clopidogrel or prasugrel with dual anti-platelet therapy after percutaneous coronary intervention in patients with advanced chronic kidney disease using a new generation drug eluting stents.
Inclusion: Over 19 years old; Chronic Renal Failure Stage IIIb, IV, V (CKD-EPI eGFR <45 / <30 / <15 or dialysis); Patients treated with a new generation drug eluting stent; Patients who signed consent form.
Exclusion: Patients with high risk of bleeding 1) History of hemorrhagic stroke 2) Stroke, dementia or central nervous system damage within 1 year 3) Head trauma or brain surgery within 6 months 4) Tumor in the skull 5) If aortic dissection is suspected 6) Internal bleeding within 6 weeks 7) In case of active bleeding or bleeding disorder 8) In case of major surgery, trauma or bleeding within 3 weeks; Patients with a history of intracranial bleeding; Moderate to severe hepatic impairment (Child-Pugh class B or C); Over 85 years old; Pregnant women or women of childbearing age; Patients who need oral anticoagulant; Life expectancy is less than 1 year.